Expertise in
1
conditions

Dr. Melanie Royce

Internal Medicine
UNM Medical Group Inc
Albuquerque, NM 
Expertise in
1
conditions
UNM Medical Group Inc
Albuquerque, NM 

Overview

Melanie Royce is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Royce is highly rated in 1 condition, according to our data. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Breast Cancer in Men, and Lymphomatoid Papulosis.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in NM

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNM Medical Group Inc
Albuquerque, NM 87102
Other Locations
University of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Expanded Breast Cancer Registry and Tissue Repository
Expanded Breast Cancer Registry and Tissue Repository
Enrollment Status: Completed
Publish Date: May 22, 2025
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Enrollment Status: Terminated
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

34 Total Publications

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 16, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Edward Lewiecki
Internal Medicine
Expertise in
12
conditions
Dr. Edward Lewiecki
Internal Medicine

New Mexico Clinical Research Osteoporosis Center Inc

300 Oak St NE, 
Albuquerque, NM 
 (0.9 miles away)
505-855-5525
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Lewiecki is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Lewiecki is highly rated in 12 conditions, according to our data. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure, and Hypogonadism Primary Partial Alopecia. Dr. Lewiecki is currently accepting new patients.

Expertise in
5
conditions
Dr. Catherine Bjerum
Internal Medicine
Expertise in
5
conditions
Dr. Catherine Bjerum
Internal Medicine

Sound Physicians Of New Mexico

2400 Unser Blvd SE, 
Rio Rancho, NM 
 (9.4 miles away)
505-253-7878
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Catherine Bjerum is an Internal Medicine provider in Rio Rancho, New Mexico. Dr. Bjerum is highly rated in 5 conditions, according to our data. Her top areas of expertise are Lymphatic Filariasis, Spirurida Infections, Secernentea Infections, and Helminthiasis. Dr. Bjerum is currently accepting new patients.

Expertise in
7
conditions
Dr. Lance Rudolph
Internal Medicine
Expertise in
7
conditions
Dr. Lance Rudolph
Internal Medicine

New Mexico Clinical Research Osteoporosis Center Inc

300 Oak St NE, 
Albuquerque, NM 
 (0.9 miles away)
505-855-5525
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lance Rudolph is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Rudolph is highly rated in 7 conditions, according to our data. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Hypogonadism Primary Partial Alopecia, and Premature Ovarian Failure. Dr. Rudolph is currently accepting new patients.

Frequently Asked Questions about Dr. Melanie Royce

How do I make an appointment with Dr. Melanie Royce?

You can book an appointment with Dr. Melanie Royce by calling their office at 505-272-4946. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Melanie Royce a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Melanie Royce is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Melanie Royce specialize in?

While Dr. Melanie Royce is a Internal Medicine, they have specific expertise in Breast Cancer, HER-2 Positive Breast Cancer, and Breast Cancer in Men. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Melanie Royce participate in research or clinical trials?

Yes. Dr. Melanie Royce has published 34 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Melanie Royce's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Royce's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile